Pravastatin sodiumCAS号： 81131-70-6分子式： C23H35NaO7分子量： 446.51描述纯度储存/保存方法别名外观可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)
| 产品描述 | |
| 描述 |
Pravastatin sodium, an HMG-CoA reductase inhibitor, inhibits sterol synthesis with IC50 of 5.6 μM. |
| 纯度 |
≥98%
|
| 储存/保存方法 |
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
|
| 基本信息 | |
| 别名 |
普伐他汀钠；CS-514 sodium
|
| 外观 |
white powder
|
| 可溶性/溶解性 |
DMSO : 100 mg/mL (223.96 mM; Need ultrasonic)
H2O : ≥ 50 mg/mL (111.98 mM) |
| 生物活性 | |
| 靶点 |
HMG-CoA reductase
|
| In vitro(体外研究) |
Pravastatin-Na at 10 μM inhibits the sterol synthesis at a level greater than 50% in PBMC. Pravastatin produces relaxation of isolated aortic rings, with maximum vasorelaxations of 62.8% at 10 μM and latency of ~8 min. Pravastatin ( Pravastatin results in a dose-dependent inhibition of macrophage cholesterol synthesis in human monocyte derived macrophages(HMDM), mouse peritoneal macrophages (MPM) and a J-774 A.1 macrophagelike cell lines. Small concentrations of pravastatin ( Pravastatin (
|
| In vivo(体内研究) |
Pravastatin (40 mg, single dose) causes a reduction in cholesterol synthesis in human monocyte derived macrophages by 62% in healthy subjects and 47% in hypercholesterolaemic patients. Pravastatin (40 mg/day, 8 weeks) results in a 55% inhibition of cholesterol synthesis and a 57% increase in LDL degradation in hypercholesterolaemic patients. Pravastatin (30 mg/kg/d) results in decreased length of the dystrophic lesions by 34% and recovery of muscular structure in Male Wistar rats receiving irradiation, associated with decreased CCN2 level.
|
分子结构图
